Early stage investor Karna D Shinde has invested in neuro42 over multiple rounds in the last few years

In a recent announcement, neuro42, a medical technology company pioneering portable MRI, robot and AI technologies has secured undisclosed investments from investor, Karna D Shinde. This is Karna’s third round of investment in the company. neuro42, a game changer technology in the field of neurosurgery recently received USFDA clearance for its innovative diagnostic MRI product. The 510(k) clearance, received in February 2024, marks a significant milestone for neuro42 and sets the stage for the commercialization of its cutting-edge diagnostic MRI machine later this year.

Karna D Shinde, an early investor in neuro42, has been closely associated with the Company since its formation, and has shown unwavering support for neuro42’s mission to revolutionize neuroimaging and interventions. Karna’s belief in the potential of neuro42 is reflected in his multiple investments in the Company, emphasizing his confidence in the impact that this platform technology can have on advancing neurosurgical outcomes.

neuro42’s portable MRI is designed to specialize in imaging the brain and head, with a key focus on MR-guided interventions. One of the primary drivers of innovation at neuro42 is its ability to amplify the capabilities of neurosurgeons, particularly in complex and time-sensitive procedures such as the treatment of brain tumors and epilepsy.

“The diagnostic and interventional capabilities of neuro42’s MRI have the potential to transform the way challenging brain tumor cases are approached and treated,“ stated Karna D Shinde, Investor and Strategic Advisor.

In the neuro intervention space, the need for advanced tools that can aid in precise diagnosis and targeted interventions is more critical than ever. The AI-driven tissue characterization feature that neuro42 is developing, provides neurosurgeons with meaningful insights and enables them to make informed decisions and improve patient outcomes.

The compact and transportable nature of neuro42’s MRI system further enhances its utility in clinical settings, offering flexibility and convenience to healthcare providers. With the interventional MRI, the ability to perform imaging and interventions can significantly reduce treatment delays and improve the overall efficiency of neurosurgical procedures.

“We are thrilled to announce the FDA clearance of our bedside MRI product. Our team has been focused on making a difference in patient care, and now we can finally arm healthcare providers with a valuable tool to improve accessibility to neuroimaging.” said Abhita Batra, Founder and Chief Strategy Officer of neuro42.

The commercialization of neuro42’s MRI and robotic platform is expected to have far-reaching implications for the field of neurosurgery, offering new possibilities for enhancing targeted treatment planning and patient care. As the Company prepares to launch its product later this year, anticipation is high within the medical community for the transformative potential of neuro42’s advanced neuroimaging solutions.

neuro42 MRI is receiving positive feedback and has generated significant interest from healthcare facilities in multiple Indian states like Telangana, Maharashtra, and Karnataka. The fact that neuro42 has obtained USFDA clearance is indeed a significant milestone for the company. This clearance not only validates the quality and safety of neuro42 MRI technology but also allows the company to expand its operations and serve a larger market, benefiting healthcare facilities, patients, and the company itself.